TRITON3: A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE 3 STUDY OF RUCAPARIB VERSUS PHYSICIAN¿S CHOICE OF THERAPY FOR PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY

Registry ID

CO-338-063

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CLOVIS ONCOLOGY INC

Start date

2021-03-09

Last update

2017-04-20

Conditions

• PROSTATE CANCER METASTATIC CASTRATION RESISTANT

Related clinical trials

• A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD2265 (FPI-2265) 225AC-PSMA-I&T COMPARED WITH STANDARD OF CARE IN PATIENTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (VECTRA-01)
• A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF XALURITAMIG PLUS ABIRATERONE VERSUS INVESTIGATOR’S CHOICE IN PARTICIPANTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
• A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, WITH DOCETAXEL VERSUS DOCETAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, + BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
• A PHASE 1/2 PLATFORM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IFINATAMAB DERUXTECAN AS MONOTHERAPY OR IN COMBINATION WITH OTHER TREATMENTS IN PARTICIPANTS WITH PROSTATE CANCER
• A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF ACTINIUM-225-MACROPA-PELGIFATAMAB (BAY 3546828) IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

View on source registry